|
1 |
Albi grade enables risk stratification for bleeding events and refines prognostic prediction in advanced HCC following atezolizumab and bevacizumab Stefanini, Bernardo. - Freiburg : Universität, 2025
|
|
|
2 |
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours Celsa, Ciro. - Freiburg : Universität, 2023
|
|
|
3 |
One Health assessment of persistent organic chemicals and PFAS for consumption of restored anadromous fish Enthalten in Journal of exposure science & environmental epidemiology 15.12.2023: 1-10
|
|
|
4 |
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study D’Alessio, Antonio. - Freiburg : Universität, 2022
|
|
|
5 |
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study Fulgenzi, Claudia Angela Maria. - Freiburg : Universität, 2022
|
|
|
6 |
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma Enthalten in Liver cancer Bd. 11, 2022, Nr. 4: 354-367. 14 S.
|
|
|
7 |
Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma Fessas, Petros. - Freiburg : Universität, 2021
|
|
|
8 |
Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI grade Pinato, David James. - Freiburg : Universität, 2020
|
|
|
9 |
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study Fessas, Petros. - Freiburg : Universität, 2020
|
|
|
10 |
Structure‐Activity Relationship and Crystallographic Studies on 4‐Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors Enthalten in ChemMedChem Bd. 15, 2020, Nr. 3: 270-273. 4 S.
|
|